Who are Aripiprazole or Perphenazine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aripiprazole-or-perphenazine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Aripiprazole or Perphenazine — Competitive Intelligence Brief

Aripiprazole or Perphenazine (Aripiprazole or Perphenazine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic (aripiprazole); Typical antipsychotic (perphenazine). Area: Psychiatry.

marketed Atypical antipsychotic (aripiprazole); Typical antipsychotic (perphenazine) Dopamine D2/D3 receptors, serotonin 5-HT1A receptor (aripiprazole); Dopamine D2 receptor (perphenazine) Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Aripiprazole or Perphenazine (Aripiprazole or Perphenazine) — Johns Hopkins University. Aripiprazole is a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A partial agonist that modulates dopaminergic and serotonergic neurotransmission; perphenazine is a typical antipsychotic that blocks dopamine D2 receptors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aripiprazole or Perphenazine TARGET	Aripiprazole or Perphenazine	Johns Hopkins University	marketed	Atypical antipsychotic (aripiprazole); Typical antipsychotic (perphenazine)	Dopamine D2/D3 receptors, serotonin 5-HT1A receptor (aripiprazole); Dopamine D2 receptor (perphenazine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic (aripiprazole); Typical antipsychotic (perphenazine) class)

Johns Hopkins University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aripiprazole or Perphenazine — Competitive Intelligence Brief. https://druglandscape.com/ci/aripiprazole-or-perphenazine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab